Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Mr. Eric  So L.L.B.

Co-Founder, President & Executive Chairman

Ms. Lori  Challenger

Chief Compliance, Ethics & Administrative Officer

Sara Brittany Somerset

Chief Communications Officers

Mr. Gabriel  Fahel

Chief Legal Officer & Corporate Secretary

Mr. Greg  Cavers

Chief Financial Officer

Dr. Alex L. Nivorozhkin Ph.D.

Chief Scientific Officer

Mr. Aaron  Bartlone

Chief Operating Officer

Mr. Paul  Glavine

Co-Founder, Chief Growth Officer & Director

Mr. Douglas L. Drysdale

Chief Executive Officer

Mr. John  Kanakis

Co-Founder

Biotechnologie

Cybin Inc.

Cybin Inc. Structure de gestion

Informations sur la direction